Circular RNA technology — the covalently closed loop RNA without 5' cap or 3' poly-A tail resisting exonuclease degradation and enabling prolonged protein expression creating the next-generation mRNA format — creates the most commercially dynamic market segment, with the mRNA Platform Market reflecting circRNA as the stability-driven commercial driver.

Orna Therapeutics and Laronde leadership — the $100M+ funded startups developing circRNA for protein replacement, CAR-T, and vaccine applications creating the commercial pioneer segment. Orna's isCAR technology (in situ CAR) with circRNA encoding CAR delivered to T cells in vivo, eliminating ex vivo cell manipulation, and Laronde's "Endless RNA" (eRNA) with proprietary translation initiation sequences and IRES-driven protein expression demonstrates the innovation commercial impact.

Non-immunogenic and non-inflammatory profile — the absence of 5' triphosphate and dsRNA byproducts in clean circRNA production creating the improved safety profile. circRNA avoiding TLR3, RIG-I, and PKR innate immune activation, enabling repeat dosing without interferon response or inflammation, and the potential for weekly or monthly dosing vs daily or weekly for conventional mRNA.

Prolonged protein expression duration — the exonuclease resistance enabling 2-4x longer protein expression than linear mRNA creating the durability advantage. Preclinical data showing 14-30 days protein expression from circRNA vs 3-7 days from linear mRNA, with the potential for chronic disease protein replacement with monthly or quarterly administration.

Do you think circRNA will overcome the manufacturing complexity, lower initial translation efficiency, and limited clinical data to become the dominant mRNA format, or will it remain a specialized platform for specific applications requiring prolonged expression?

What are the specific circRNA technologies, their mechanisms, and development status? Mechanism: circularization: covalent; 3'-5' phosphodiester; bond; no; free; ends; exonuclease; resistant; no; cap; no; poly-A; IRES: internal; ribosome; entry; site; translation; initiation; no; 5' cap; required; eIF4G; independent; optimized; IRES; sequences; proprietary; each; company; purification: high; purity; required; linear; precursor; removal; critical; HPLC; enzymatic; methods; Orna Therapeutics: isCAR: in situ; CAR; circRNA; encoding; CAR; delivered; to; T cells; in vivo; ex vivo; elimination; simplified; manufacturing; funding: $100M+; Series A; B; Merck; collaboration; $3.5B; potential; milestones; status: preclinical; CAR-T; oncology; protein replacement; emerging; Laronde (Flagship Pioneering): eRNA: Endless; RNA; proprietary; IRES; translation; eVLP: endogenous; virus-like; particle; delivery; system; funding: $50M+; Flagship; capital; status: preclinical; various; indications; emerging; Chimerna Therapeutics: circRNA: therapeutic; applications; protein; replacement; vaccine; funding: $30M+; seed; Series A; status: preclinical; research; early; academic: Stanford: circRNA; research; Howard; Chang; lab; foundational; science; MIT: Daniel; Anderson; lab; circRNA; delivery; LNP; optimization; various: global; research; 50+ labs; circRNA; biology; therapeutic; potential; Status: all preclinical: no; circRNA; therapeutic; in; clinical; trials; yet; 2025+; earliest; Phase I; expected; if; successful; Challenges: manufacturing: circularization; efficiency; 50-80%; linear; precursor; removal; difficult; purity; critical; translation: IRES; efficiency; lower; than; 5' cap; 20-50%; of; cap-dependent; translation; optimization; needed; clinical: no; human; data; safety; efficacy; unknown; immunogenicity; theoretical; advantage; not; proven; in; humans; yet; Future: optimization: IRES; engineering; higher; efficiency; translation; initiation; sequences; proprietary; competitive; advantage; delivery: LNP; optimization; circRNA; specific; size; charge; stability; different; from; linear; mRNA; combination: circRNA + gene; editing; CRISPR; guide; RNA; prolonged; expression; reduced; dosing; frequency; protein replacement: monthly; quarterly; administration; chronic; disease; hemophilia; Fabry; Pompe; potential; cancer: prolonged; antigen; expression; vaccine; reduced; booster; frequency; in situ; CAR; T cell; engineering; simplified.